Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Immunotherapy has emerged as a promising treatment paradigm for many malignancies
and is transforming the drug development landscape. Although immunotherapeutic agents …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Cancer immunotherapy has made remarkable progress in the past decade. Bispecific
antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody …

Purpose: Investigate the safety and efficacy of LY3415244, a TIM-3/PD-L1 bispecific
antibody that blocks TIM-3 and PD-L1 in patients with advanced solid tumors. Patients and …

Cytotoxic T cells initiate antitumor effects mainly through direct interactions with tumor cells.
As a counter to this, tumor cells can put the brakes on such T-cell activity via specific linkage …

Building upon the resounding therapeutic success of monoclonal antibodies, and supported
by accelerating progress in engineering methods, the field of multispecific therapeutic …

Immune therapies have had limited efficacy in high-grade serous ovarian cancer (HGSC), as
the cellular targets and mechanism (s) of action of these agents in HGSC are unknown. Here …

Hepatocellular carcinoma (HCC) is one of the most lethal tumors in China and worldwide,
although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been …